<DOC>
	<DOCNO>NCT00003238</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness perillyl alcohol treat patient metastatic prostate cancer respond hormone therapy androgen .</brief_summary>
	<brief_title>Perillyl Alcohol Treating Patients With Metastatic Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate clinical effectiveness oral perillyl alcohol give patient androgen independent metastatic prostate cancer . II . Assess toxicity treatment patient . OUTLINE : Patients receive oral perillyl alcohol 4 time day 4 week . Patients continue treatment absence severe toxicity disease progression . Patients follow every 3 month survival disease progression . PROJECTED ACCRUAL : This study accrue 20-40 patient approximately 2 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Perilla alcohol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm progressive metastatic progressive regional nodal adenocarcinoma prostate Regression tumor follow hormone therapy If antiandrogen therapy , must fail respond withdrawal progressive disease follow withdrawal antiandrogen No CNS disease PATIENT CHARACTERISTICS : Age : Not specify Performance status : WCCC 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3000/mm3 Absolute neutrophil count least 1200/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8 g/dL Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2.5 time normal Renal : Creatinine great 1.5 time upper limit normal Other : At least 5 year since prior malignancy : Inactive nonmelanoma skin cancer Adequately treat stage I II cancer complete remission No serious illness No spinal cord compression symptom PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior chemotherapy require Endocrine therapy : Failed one secondary hormonal manipulation metastatic disease Concurrent testicular androgen suppression ( LHRH ) allow No concurrent hormonal therapy LHRH agonist At least 4 week since antiandrogen treatment order evaluate response withdrawal Radiotherapy : At least 4 week since prior radiation therapy No prior strontium therapy Surgery : No prior orchiectomy Other : No concurrent cholesterol lower agent No concurrent supplemental vitamins No concurrent antioxidant</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>recurrent prostate cancer</keyword>
</DOC>